How Creative Chemistry and Collaboration Synthesized a Better Drug Strategy For Enterin
Details : Enterin completed the first human clinical trials for ENT-01 which demonstrated that oral administration of its treatment has restored function of the nervous system of the gastrointestinal tract in Parkinson’s patients.
Brand Name : ENT-01
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 28, 2022
Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia
Details : ENT-01 is administered orally and acts locally on the ENS. It dislodges αS aggregates and inhibits their formation, restoring the firing potential of enteric neurons.
Brand Name : ENT-01
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 13, 2022
Enterin to Present at Chardan's Virtual 3rd Annual Microbiome Medicines Summit
Details : Dr. Denise Barbut, Enterin's co-founder and CMO, will present the company's latest updates relating to its lead compound, ENT-01, which is currently being developed for the treatment of Parkinson's Disease (PD).
Brand Name : ENT-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 01, 2021
LOOKING FOR A SUPPLIER?
Reset All
Pfizer CentreOne is a global CDMO and a leading supplier of Specialty APIs.
